<DOC>
	<DOCNO>NCT00576758</DOCNO>
	<brief_summary>This study investigate efficacy weekly intravenous obinutuzumab [ GA101 ( RO5072759 ) ] monotherapy , patient relapse CD20+ indolent Non-Hodgkin 's Lymphoma . Patients randomize receive either GA101 rituximab , give four weekly infusion . At conclusion initial trial patient may eligible continue therapy 24 month . The anticipated time study treatment 3- 24 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>GAUSS : A Study Obinutuzumab ( RO5072759 ) Patients With Indolent Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>adult patient , &gt; =18 year age relapse CD20+ indolent Bcell nonHodgkin 's lymphoma document history response &gt; /= 6 month duration last rituximabcontaining regimen clinical indication treatment determine investigator Eastern Cooperative Oncology Group ( ECOG ) performance status 02 prior use investigational monoclonal antibody within 6 month study start prior use anticancer vaccine prior use rituximab within 8 week study entry radioimmunotherapy within 3 month prior study entry Central Nervous System ( CNS ) lymphoma evidence transformation highgrade diffuse large Bcell lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>